Ireland’s Cosmo Pharma claimed FDA approval for its traveller’s diarrhoea drug Aemcolo, which some analysts say could be a big threat to a rival drug sold by Bausch Health’s Salix unit.
The U.S. Food and Drug Administration today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers' diarrhea